BOSTON, May 6, 2022
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:
NRBO), a clinical-stage biotechnology company, today announced the
appointment, effective April 30, 2022
of Matthew Bardin, PharmD, BCPS as
Senior Vice President, Operations. Reporting directly to President
and Chief Executive Officer, Gil
Price, M.D., Dr. Bardin will be responsible for day to day
operations, with a focus on clinical development.
"Matthew is a highly experienced pharmaceutical professional who
brings to NeuroBo an extensive track record of clinical drug
development, medical affairs and oversight expertise in a number of
therapeutic areas, most importantly within the area of infectious
diseases and gastroenterology," stated Gil
Price, M.D., President and Chief Executive Officer of
NeuroBo. "We are excited to welcome Matthew to our team, especially
as we continue to advance our lead drug candidate, ANA001, and
continue to identify new products for licensure and
development."
Prior to joining NeuroBo, Dr. Bardin held positions of
increasing responsibility at Romark, L.C., a vertically integrated,
research-based pharmaceutical company focused primarily on
gastroenterology and infectious diseases, where he most recently
served as Vice President, Medical Affairs/Research and Development.
During his tenure at Romark, Dr. Bardin was responsible for all
clinical drug development, medical affairs activities, and
pharmacovigilance oversight for the company. Before that, Dr.
Bardin was with Clinical Pharmacology Services, Inc./Conexus
Health, a company dedicated to improving medication use, patient
safety and health outcomes, last holding the position of Clinical
Services Manager. Earlier in his career, Dr. Bardin was a Pharmacy
Clinical Coordinator at South Florida Baptist Hospital and was a
Pharmacy Practice Resident at Piedmont Hospital, in Atlanta, GA.
Dr. Bardin is the co-author of numerous publications and
abstracts in the area of gastroenterology and infectious diseases.
He earned a Doctor of Pharmacy degree from Samford University McWhorter School of Pharmacy,
Birmingham, AL and a Bachelor of
Science, Biochemistry from Florida State
University in Tallahassee,
FL. He is a Certified MedDRA Coder, a Board Certified
Pharmacotherapy Specialist and holds both a Florida Pharmacist and
Florida Consultant Pharmacist License.
Forward Looking Statements
Any statements in this
press release that are not statements of historical fact constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements include, but are not limited to, statements regarding
NeuroBo's development expenses, the development of NeuroBo's
product candidates and the therapeutic potential, timing and nature
of clinical trials and potential regulatory approval of NeuroBo's
clinical programs and pipeline. Forward-looking statements are
usually identified by the use of words, such as "believes,"
"anticipates," "expects," "intends," "plans," "may," "potential,"
"will," "could" and similar expressions. Actual results may differ
materially from those indicated by forward-looking statements as a
result of various important factors and risks. These factors, risks
and uncertainties include, but are not limited to: recent changes
in NeuroBo's management; the failure to obtain all of the benefits
or recognize all of the synergies anticipated from the ANA
acquisition; the integration of ANA potentially diverting
management resources from operational matters and other strategic
opportunities; the effect of future milestone payments and
royalties specified in the ANA acquisition agreement on the results
of operations and financial position of NeuroBo; the occurrence of
health epidemics or contagious diseases, such as COVID-19, and
potential effects on NeuroBo's business, clinical trial sites,
supply chain and manufacturing facilities; NeuroBo's ability to
continue as a going concern; the timing of completion of NeuroBo's
planned clinical trials, including with respect to ANA001 and
Gemcabene; the timing of the availability of data from NeuroBo's
clinical trials, including with respect to ANA001 and Gemcabene;
NeuroBo's plans to research, develop and commercialize its current
and future product candidates, including the potential alternative
pathways for NB-01; NeuroBo's ability to successfully collaborate
with existing collaborators or enter into new collaborations and to
fulfill its obligations under any such collaboration agreements;
the clinical utility, potential benefits and market acceptance of
NeuroBo's product candidates, including ANA001 and Gemcabene; the
impact of government laws and regulations; NeuroBo's ability to
protect its intellectual property position; and NeuroBo's need for
additional financing to fulfill its stated goals. Please
refer to NeuroBo's most recent annual report on Form 10-K, as well
as NeuroBo's subsequent filings on Form 10-Q and Form 8-K, which
are available on the SEC's website (www.sec.gov), for a full
discussion of the risks and other factors that may impact any
forward-looking statements in this press release. In addition, the
forward-looking statements included in this press release represent
NeuroBo's views as of the date hereof. NeuroBo anticipates that
subsequent events and developments will cause its views to change.
However, while NeuroBo may elect to update these forward-looking
statements at some point in the future, NeuroBo specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing NeuroBo's views as of any
date subsequent to the date hereof.
Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-inc-expands-management-team-with-the-appointment-of-matthew-bardin-pharmd-bcps-as-senior-vice-president-operations-301541550.html
SOURCE NeuroBo Pharmaceuticals, Inc.